MAPT and tauopathy: We found that removal of TMEM16F in the PS19 mouse model of tauopathy was protective at 6 to 7 mo of age, as indicated by the reduction of pathology in both the number of neurons with pathogenic hyperphosphorylated tau and the levels of microgliosis within the hippocampus (Figs. 1, –3).